Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-101orevantinibVRX-1 solid tumorsOncology · Small molecule
Label expansion filing 2027
CLV-114tazulimab-cvraMultiple myelomaOncology · Antibody
Earlier-line data H1 2027
CLV-122berolumab-cvraHER-low breast cancer (first line)Oncology · ADC
Regulatory decision Q2 2027
CLV-131emzaratinibNSCLC adjuvantOncology · Small molecule
Phase 3 readout 2027
CLV-140Small cell lung cancerOncology · Bispecific
Phase 2 data at oncology congress
CLV-147Ovarian cancerOncology · ADC
Dose escalation complete
CLV-158Pancreatic cancer (KRAS)Oncology · Small molecule
IND filing 2027
Pipeline as of September 30, 2026. Programs and data are fictional.